-
Atara Biotherapeutics, Inc. (NASDAQ: ATRA)
Atara is harnessing the natural power of the immune system to develop and investigate off-the-shelf cell therapies that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. We are focused on applying Epstein-Barr virus (EBV) T-cell biology, featuring experience in over 600 patients treated with allogeneic EBV T cells, and novel chimeric antigen receptor (CAR) technologies to meet the current limitations of autologous and allogeneic CAR therapies head-on by advancing a potential best-in-class CAR T pipeline in oncology and autoimmune disease. Our platform is unique—αβ T cells that require no T-cell receptor or human leukocyte antigen gene editing—and it’s what makes Atara well-positioned to deliver on our goal of bringing off-the-shelf immunotherapies to patients in need. Atara is headquartered in Southern California.
Jason Awe, PhD, MBA
Head of Corporate Communications and Investor Relations
Dr. Jason Awe serves as Head of Corporate Communications and Investor Relations at Atara Biotherapeutics, where he focuses on enterprise communication strategies and building Atara’s presence and relationships with the analyst and investor community in support of advancing the development of next-generation allogeneic T-cell therapies for cancer and autoimmune diseases. With significant academic research experience in stem cell technology, molecular biology, and immunology, he has a strong ability to interpret complex scientific content to craft understandable and impactful communications that resonate with various stakeholders including the investment community. Prior to Atara, Dr. Awe was at Amgen in a variety of diverse roles across medical, value and access, and policy communications spanning oncology, hematology, and inflammation. He received his undergraduate degree in Pharmacology from the University of California, Santa Barbara, PhD in Molecular and Medical Pharmacology from UCLA, and MBA from UCLA Anderson School of Management.